Table 3.
The prevalence (p) of HIV treatment failure based on HAART failure, immunological, virological, and clinical definition when the study omitted in Ethiopia
| Study omitted | HAART failure P (95%CI) | Immunological failure P (95%CI) | Virological failure P (95%CI | Clinical failure P (95% CI) |
|---|---|---|---|---|
| Bokretsion BG et al./2017 | 15.3 (10.8–19.9) | 9.7 (6.3–13.2) | 4.5 (2.3–6.7) | 5.6 (4.2–7.1) |
| Yassin S /2017 | 15.5 (10.9–20.1) | 10.5 (6.9–14.1) | __ | 5.5 (4.1–7.1) |
| Zeleke A/2016 | 15.6 (11.0–20.2) | 10.6 (7.0–14.1) | __ | 6.7 (4.9–8.4) |
| Yimer YT/2015 | 15.4 (10.8–19.9) | 9.8 (6.4–13.3) | 6.5 (2.7–10.3) | 6.3 (4.4–8.2) |
| Bacha T et al./2012 | 16.1 (10.9–21.3) | 10.5 (6.6–14.4) | __ | 6.4 (4.3–8.4) |
| Ayalew MB et al./2016 | 17.3 (13.5–21.2) | 10.8 (7.1–14.4) | 6.0 (2.9–9.2) | __ |
| Sisay MM et al./2018 | 16.9 (12.6–21.2) | 10.9 (7.7–14.1) | __ | 6.4 (4.4–8.4) |
| Tsegaye AT et al./2016 | 15.5 (10.9–20.1) | 10.5 (6.9–14.1) | __ | 6.7 (5.0–8.4) |
| Teshome W/2015 | __ | 9.8 (6.3–13.2) | __ | __ |
| Hailu GG et al./2015 | __ | 10.5 (6.9–14.1) | 4.4 (2.0–6.9) | __ |
| Yayehirad AM et al./2013 | __ | 9.3 (6.3–12.4) | __ | __ |
| Workneh N et al./2009 | __ | 10.1 (6.6–13.6) | ___ | 6.4 (4.6–8.2) |
| Sisay C et al./2017 | 15.2 (10.8–19.5) | 9.8 (6.4–13.2) | 6.4 (2.4–10.4) | 6.5 (4.7–8.4) |
| Abdissa A et al./2014 | __ | __ | 5.6 (2.7–8.6) | __ |
| Combined | 15.8 (11.6–20.1) | 10.2 (6.8–13.6) | 5.6 (2.9–8.3) | 6.3 (4.6–7.9) |
__ denotes no estimation due to lack of original studies